Certified by Founder
Lodge
Brightstar Therapeutics
start up
United States
- Lexington, Kentucky
- 21/04/2023
- Series A
- Undisclosed Amount
Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with corneal and ocular surface diseases.
Brightstar Therapeutics is the first company to offer a long-term solution for persistent epithelial defects, and partial limbal stem cell deficiency through its advanced corneal allograft, BrightMEM.
- Industry Hospital & Health Care
- Website https://www.brightstartx.com/
- LinkedIn https://www.linkedin.com/company/brightstar-therapeutics/
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)